Oxford Immunotec Global PLC Rating Reiterated by JPMorgan Chase & Co. (OXFD)
Oxford Immunotec Global PLC (NASDAQ:OXFD)‘s stock had its “overweight” rating reiterated by stock analysts at JPMorgan Chase & Co. in a report issued on Wednesday. They currently have a $23.00 target price on the stock, down from their previous target price of $26.00. JPMorgan Chase & Co.’s target price points to a potential upside of 63.00% from the stock’s previous close.
Oxford Immunotec Global PLC (NASDAQ:OXFD) traded down 6.86% during mid-day trading on Wednesday, hitting $14.11. The stock had a trading volume of 48,775 shares. Oxford Immunotec Global PLC has a one year low of $13.58 and a one year high of $25.38. The stock has a 50-day moving average of $16.86 and a 200-day moving average of $19.26. The company’s market cap is $247.8 million.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.16. The company had revenue of $11.80 million for the quarter, compared to the consensus estimate of $11.39 million. The company’s revenue for the quarter was up 15.7% on a year-over-year basis. Analysts expect that Oxford Immunotec Global PLC will post $-0.80 EPS for the current fiscal year.
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company. The Company’s T-SPOT technology platform allows the Company to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.